Amplia Therapeutics Ltd has released a press release.
CEO Resignation
Filed with ASX ·
On 6ix: 6ix.com/news/ceo-resignation-4
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Amplia Receives $1.8m R&D Tax Incentive
- CEO & Managing Director Presentation to AGM
- First Patient Recruited to ACCENT Trial in Pancreatic Cancer
- Quarterly Activities and Cashflow Reports - June 2022 Qtr
- AMP945 Shows Efficacy in Model of Lung Fibrosis
Later from Amplia Therapeutics
- AMP886 Activity in Acute Myeloid Leukemia
- Quarterly Activities and Cashflow Reports - Sep 2022 Qtr
- Amplia Appoints Dr Christopher Burns CEO & Managing Director
- Appendix 4D and Financial Report Half Year ended 30 Sep 22
- Letter to Shareholders End of Year Summary and 2023 Plans
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics